



LEAD-1 SU study group

Contact

LEAD-1 SU study group

Publications (1)

Marre M, Colagiuri S, Le Thi T, Zdravkovic M, Strand J, Kamaruddin N, Bebakar W, Brändle M, Shaw J, LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabetic medicine : a journal of the British Diabetic Association* 2009; 26:268-78.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch